MHRA consulting for ‘no deal’ Brexit
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is consulting on proposed changes to the way it would regulate medicinal products in the country in the event of a ‘no deal’ UK exit from the European Union (EU) on 29 March 2019.